一个基因型到药物扩散模型,用于生成定制的抗癌小分子
Hyunho Kim1,2, Bongsung Bae1, Minsu Park1
1Department of Electrical Engineering and Computer Science, Gwangju Institute of Science and Technology, Gwangju, Republic of Korea.
Nature communications
|July 2, 2025
概括
生成性AI设计了针对特定癌症基因型的新型抗癌药物. 这种方法通过识别有效的分子和挑战癌症的潜在目标来加速个性化药物发现.
科学领域:
- 计算生物学 计算生物学
- 药物发现 药物发现 药物发现
- 人工智能的人工智能
背景情况:
- 精确瘤学面临着瘤异质性和有限的药物点的挑战.
- 生成性人工智能为基于基因组数据设计抗癌分子提供了一种新的方法.
研究的目的:
- 引入基因型到药物扩散 (G2D-Diff),一种用于设计针对特定癌症基因型的小分子药物的生成性AI模型.
- 评估G2D-Diff在产生多样化,有效和可行的候选药物方面的表现.
主要方法:
- 开发了G2D-Diff,一种利用扩散方法的生成AI模型.
- 在药物反应数据上训练模型,以学习基因型特定的疗效条件.
- 包含了用于目标和路径识别的注意力机制.
主要成果:
- G2D-Diff产生了各种各样的类似药物的化合物,符合特定的疗效标准.
- 该模型在多样性,可行性和条件适应性方面超过了现有的方法.
- 在三阴性乳腺癌的案例研究确定了可信的候选药物和相关途径.
结论:
- G2D-Diff代表了人工智能引导的个性化药物发现的重大进步.
- 该模型有效地将分子生成与特定基因型的途径识别相结合.
- 这种方法有可能加速对具有挑战性的癌症的命中鉴定.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Targets for Drug Action: Overview
7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K


